title: Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid?
abstract: Cerebrospinal fluid (CSF) measures of amyloid and tau are the first-line Alzheimer's disease biomarkers in many clinical centers. We assessed if and when the addition of amyloid PET following CSF measurements provides added diagnostic value. Twenty patients from a cognitive clinic, who had undergone detailed assessment including CSF measures, went on to have amyloid PET. The treating neurologist's working diagnosis, and degree of diagnostic certainty, was assessed both before and after the PET. Amyloid PET changed the diagnosis in 7/20 cases. Amyloid PET can provide added diagnostic value, particularly in young-onset, atypical dementias, where CSF results are borderline and diagnostic uncertainty remains.
authors: Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.
authors: Philip S J
authors: PS
authors: Weston
authors: Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.
authors: Ross W
authors: RW
authors: Paterson
authors: Institute of Nuclear Medicine, University College London Hospitals, London, UK.
authors: John
authors: J
authors: Dickson
authors: Institute of Nuclear Medicine, University College London Hospitals, London, UK.
authors: Anna
authors: A
authors: Barnes
authors: Institute of Nuclear Medicine, University College London Hospitals, London, UK.
authors: Jamshed B
authors: JB
authors: Bomanji
authors: Institute of Nuclear Medicine, University College London Hospitals, London, UK.
authors: Irfan
authors: I
authors: Kayani
authors: Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, UK.
authors: Michael P
authors: MP
authors: Lunn
authors: Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.
authors: Catherine J
authors: CJ
authors: Mummery
authors: Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.
authors: Jason D
authors: JD
authors: Warren
authors: Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.
authors: Martin N
authors: MN
authors: Rossor
authors: Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.
authors: Nick C
authors: NC
authors: Fox
authors: Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, UK.|Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
authors: Henrik
authors: H
authors: Zetterberg
authors: Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.
authors: Jonathan M
authors: JM
authors: Schott
mesh_terms: D000368:Aged; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid*; D015415:Biomarkers / Q000134:cerebrospinal fluid; D003704:Dementia / Q000134:cerebrospinal fluid* / Q000000981:diagnostic imaging*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000134:cerebrospinal fluid*; D049268:Positron-Emission Tomography / Q000592:standards; D016875:tau Proteins / Q000134:cerebrospinal fluid*
chemical_list: D016229:Amyloid beta-Peptides; D015415:Biomarkers; C054369:MAPT protein, human; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42); D016875:tau Proteins
keywords: Alzheimer’s disease; PET; biomarker; cerebrospinal fluid; clinical decision-making; diagnosis